FDA Reviews Semax, Epitalon, and DSIP-Related Bulk Substances

FDA’s July 24, 2026 presentation on Semax, Epitalon, and Emideltide/DSIP-related bulk substances is best read as an evidence and identity audit. It was not a drug-approval review, and it did not establish final compounding policy. The nominations had been withdrawn; FDA continued to evaluate the related free-base and acetate forms at its own discretion and brought questions to an advisory committee.

The official meeting page records three use sets: Emideltide/DSIP-related substances for opioid withdrawal, chronic insomnia, and narcolepsy; Epitalon-related substances for insomnia; and Semax-related substances for cerebral ischemia, migraine, and trigeminal neuralgia. Those are uses FDA evaluated, not uses the agency recognized as safe or effective.

Claim audit: “DSIP” was a simple, settled identity

FDA did not treat the naming record as simple. In its July 24 presentation package, the agency described Emideltide as a common name rather than a United States Adopted Name, International Nonproprietary Name, or systematic IUPAC name. It found inconsistencies between the withdrawn nominations, the stated name, identifiers, molecular information, and certificates of analysis.

FDA therefore evaluated Emideltide free base and Emideltide acetate while discussing the common “DSIP” label cautiously. The presentation shows why this is more than a semantic dispute: free base and acetate are distinct bulk drug substances, and a different molecular formula in submitted paperwork may point to a different material altogether.

The agency’s preliminary balance weighed against placing either evaluated Emideltide form on the 503A Bulks List. It cited weak physical and chemical characterization, insufficiently characterized human safety data, possible immunogenicity concerns, and a lack of evidence supporting effectiveness for the three reviewed conditions.

That conclusion is preliminary and process-specific. It does not prove that every paper using “DSIP” studied the same substance, and that uncertainty is part of the problem rather than a loophole around it.

Claim audit: Epitalon had an established human safety record

FDA’s presentation does not support that claim. The agency said it had not identified clinical studies designed to assess the safety of Epitalon administered to humans. It discussed a small study that did not report safety data and an abstract that lacked enough detail to characterize exposure or outcomes. An absence of adverse-event reports in database searches was not treated as proof of safety because reporting is voluntary and particularly incomplete for compounded products.

For the nominated insomnia context, FDA found limited effectiveness evidence and insufficient information to support human safety, including for the proposed use context. It also raised characterization and potential immunogenicity questions. The preliminary balance weighed against listing Epitalon free base or Epitalon acetate.

Readers familiar with the Jacked Forums Epitalon reference should keep the page types separate. An entity overview can describe published hypotheses and historical research. A 503A evaluation asks whether specified bulk substances meet the factors FDA applies to compounded-drug eligibility. Neither page creates an approved use.

Claim audit: One Semax adverse-event report proves causation

No. FDA reported one FAERS case involving eye pain and burning after use of a product described as Semax nasal drops purchased online, followed by hospitalization and persistent symptoms. The presentation also states the limitations of FAERS: reports are voluntary, information may be incomplete, and a report alone cannot establish that a product caused an event or tell how often an event occurs.

The correct use of the case is modest. It is a safety signal in the review record, not a controlled comparison and not an incidence estimate. Product identity and other factors may also be uncertain when material is obtained outside an approved supply chain.

FDA separately reported no published human pharmacokinetic studies for Semax free base or Semax acetate through any route and no safety data for the proposed use context. It found the effectiveness evidence insufficient for cerebral ischemia, migraine, and trigeminal neuralgia. Characterization, container-and-pump questions for a nasal product, historical-use gaps, and possible immunogenicity also informed the preliminary balance against listing both forms.

The Semax reference can provide background on the name and research record, but it does not turn the FDA presentation into an administration guide. This article intentionally provides no dosing, route, stacking, or sourcing instructions.

What the committee was actually asked

The FDA meeting questions separated each subject into free-base and acetate forms. That detail blocks a common misreading in which a vote or recommendation about one named group is treated as a universal finding about every salt, derivative, product, or study carrying a similar label.

The advisory process generally follows this sequence:

1. FDA reviews characterization, historical use, available effectiveness evidence, and safety concerns.
2. FDA presents its preliminary analysis to the Pharmacy Compounding Advisory Committee.
3. Committee members discuss and provide recommendations on the stated questions.
4. FDA considers the advice and completes its own review before any final agency action.

Advisory committee recommendations are non-binding. The July documents were presentations, proposed conclusions, and voting questions—not a final rule, marketing approval, recall, or clinical guideline.

The shared issue across three very different names

Semax, Epitalon, and Emideltide/DSIP were nominated for different conditions and came with different evidence records. Treating them as a single “peptide ban” would erase those differences. What connects the reviews is the regulatory framework and the agency’s repeated concern that common names, incomplete characterization, sparse human data, and unclear historical compounding use make evidence difficult to transfer to a specific bulk drug substance.

That is also why isolated claims should not carry more weight than the underlying study design. Animal pharmacology is not human effectiveness. A human paper that does not collect safety outcomes is not a safety trial. A database with no reports is not evidence of zero risk, while one voluntary report does not prove causation. A named peptide in a publication is not automatically identical to a free base, acetate, or commercial material offered under the same common label.

As of the reviewed materials, FDA’s preliminary balances weighed against including the evaluated forms on the 503A Bulks List. The careful version ends there: the proceeding was advisory, the nominations had been withdrawn, and FDA retained responsibility for a later final determination.